Novartis Pharmaceuticals recently received FDA approval for panobinostat, a blood cancer drug that targets multiple myeloma. This was a surprising ruling, as it was a turnaround from last year’s Oncologic Drugs Advisory Committee’s 5-2 [...]
A recent report from the Institute of Medicine outlines the advantages of data sharing from clinical trials. The authors state that data sharing can lead to the discovery of new treatment modalities as well [...]
The sixth annual Partnering for Cures meeting sponsored by FasterCures was held November 16-18 in New York City. Over 1,000 attendees from biopharma, governmental agencies, academia, philanthropy and patient advocacy organizations came together to explore [...]
A recent study by Margaret von Mehren, MD and Dr. Natthapol Songdej of Fox Chase Cancer Center discusses the role of new treatments for GIST
The future of cancer treatment relies on patient enrollment in clinical trials. In a recent Chicago Tribune article, a patient story is highlighted to illustrate the important role clinical trials play in cancer treatment, not only in [...]
At the recent American Society of American Oncology Meeting (ASCO), Dr. George Demetri, Director of the Center for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute, Boston, presented results from a collaborative trial that indicates in [...]
A recent article from Cancer Research UK discusses immunotherapy, and the attention its role in the future of cancer treatment may play. In response to the interest in immunotherapy at the 50th Annual Meeting of [...]
Research!America and the Pancreatic Cancer Action Network held a meeting in New York this year to discuss ways to restructure clinical trials to find a cure for cancer.
A recent clinical trial found that 1 year of adjuvant imatinib was able to increase recurrence-free survival. Keep reading to learn more.
Accomplishments—Recent Progress: 1. Using mouse models, successfully attacked GIST with antibodies, essentially telling immune system to eat the cancer cells.
